1. Comparison of the physiological relevance of systemic vs. portal insulin delivery to evaluate whole body glucose flux during an insulin clamp. Farmer TD, Jenkins EC, O'Brien TP, McCoy GA, Havlik AE, Nass ER, Nicholson WE, Printz RL, Shiota M (2015) Am J Physiol Endocrinol Metab 308(3): E206-22
    › Primary publication · 25516552 (PubMed) · PMC4312835 (PubMed Central)
  2. Interaction between the central and peripheral effects of insulin in controlling hepatic glucose metabolism in the conscious dog. Ramnanan CJ, Kraft G, Smith MS, Farmer B, Neal D, Williams PE, Lautz M, Farmer T, Donahue EP, Cherrington AD, Edgerton DS (2013) Diabetes 62(1): 74-84
    › Primary publication · 23011594 (PubMed) · PMC3526039 (PubMed Central)
  3. Effects of intraportal exenatide on hepatic glucose metabolism in the conscious dog. Edgerton DS, An Z, Johnson KM, Farmer T, Farmer B, Neal D, Cherrington AD (2013) Am J Physiol Endocrinol Metab 305(1): E132-9
    › Primary publication · 23673158 (PubMed) · PMC3725568 (PubMed Central)
  4. Effect of the glucagon-like peptide-1 receptor agonist lixisenatide on postprandial hepatic glucose metabolism in the conscious dog. Moore MC, Werner U, Smith MS, Farmer TD, Cherrington AD (2013) Am J Physiol Endocrinol Metab 305(12): E1473-82
    › Primary publication · 24148347 (PubMed) · PMC3882379 (PubMed Central)
  5. Endogenously released GLP-1 is not sufficient to alter postprandial glucose regulation in the dog. Johnson KM, Farmer T, Schurr K, Patrick Donahue E, Farmer B, Neal D, Cherrington AD (2011) Endocrine 39(3): 229-34
    › Primary publication · 21547512 (PubMed) · PMC5371028 (PubMed Central)
  6. Brain insulin action augments hepatic glycogen synthesis without suppressing glucose production or gluconeogenesis in dogs. Ramnanan CJ, Saraswathi V, Smith MS, Donahue EP, Farmer B, Farmer TD, Neal D, Williams PE, Lautz M, Mari A, Cherrington AD, Edgerton DS (2011) J Clin Invest 121(9): 3713-23
    › Primary publication · 21865644 (PubMed) · PMC3163950 (PubMed Central)
  7. Insulin-induced hypoglycemia increases hepatic sensitivity to glucagon in dogs. Rivera N, Ramnanan CJ, An Z, Farmer T, Smith M, Farmer B, Irimia JM, Snead W, Lautz M, Roach PJ, Cherrington AD (2010) J Clin Invest 120(12): 4425-35
    › Primary publication · 21084754 (PubMed) · PMC2993579 (PubMed Central)
  8. Effect of 11 beta-hydroxysteroid dehydrogenase-1 inhibition on hepatic glucose metabolism in the conscious dog. Edgerton DS, Basu R, Ramnanan CJ, Farmer TD, Neal D, Scott M, Jacobson P, Rizza RA, Cherrington AD (2010) Am J Physiol Endocrinol Metab 298(5): E1019-26
    › Primary publication · 20159854 (PubMed) · PMC2867371 (PubMed Central)
  9. Portal infusion of escitalopram enhances hepatic glucose disposal in conscious dogs. An Z, Moore MC, Winnick JJ, Farmer B, Neal DW, Lautz M, Smith M, Rodewald T, Cherrington AD (2009) Eur J Pharmacol 607(1-3): 251-7
    › Primary publication · 19326481 (PubMed) · PMC2775505 (PubMed Central)
  10. Intraportally delivered GLP-1, in the presence of hyperglycemia induced via peripheral glucose infusion, does not change whole body glucose utilization. Johnson KM, Edgerton DS, Rodewald T, Scott M, Farmer B, Neal D, Cherrington AD (2008) Am J Physiol Endocrinol Metab 294(2): E380-4
    › Primary publication · 18056788 (PubMed)